000343938 001__ 343938
000343938 005__ 20230827173443.0
000343938 0247_ $$2CORDIS$$aG:(EU-Grant)101113278$$d101113278
000343938 0247_ $$2CORDIS$$aG:(EU-Call)ERC-2022-POC2$$dERC-2022-POC2
000343938 0247_ $$2originalID$$acorda_____he::101113278
000343938 035__ $$aG:(EU-Grant)101113278
000343938 150__ $$aPharmacoepigenetics for precision medicine in type 2 diabetes$$y2023-10-01 - 2025-03-31
000343938 372__ $$aERC-2022-POC2$$s2023-10-01$$t2025-03-31
000343938 450__ $$aProceed$$wd$$y2023-10-01 - 2025-03-31
000343938 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000343938 680__ $$aThe prevalence of diabetes will rise to ~592 million in 2035. Type 2 diabetes (T2D) is a leading cause of death through its vascular complications. High glucose increases the risk for complications, and thereby suffering for patients and costs for society. It is important that patients with T2D receive an optimal therapy that lowers blood glucose. Metformin is first-line T2D therapy. However, ~30% of patients do not respond to metformin. Currently, there are no biomarkers that predict the response to metformin. We discovered blood-based epigenetic markers that could discriminate between responders/non-responders to metformin in drug-naïve patients with T2D. This epigenetic tool may be further developed to help patients with T2D receive an optimal therapy. The aim of PROCEED is therefore to develop and commercialize our pharmacoepigenetic tool. We expect this biomarker tool to aid clinical decision-making in T2D therapy.
000343938 909CO $$ooai:juser.fz-juelich.de:1013298$$pauthority:GRANT$$pauthority
000343938 909CO $$ooai:juser.fz-juelich.de:1013298
000343938 980__ $$aG
000343938 980__ $$aCORDIS
000343938 980__ $$aAUTHORITY